Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study
Brief Summary: The purpose of the study is to evaluate non-inferiority of oral anticoagulant (OAC) monotherapy to OAC plus single antiplatelet therapy (APT) in patients with atrial fibrillation (AF) and prior (\>12 months) coronary stenting.


Options:
A: Arm Label: Stratum 1/ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid, Drug: Clopidogrel | Arm Label: Stratum 1/Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Clopidogrel | Arm Label: Stratum 2/ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid, Drug: Ticagrelor | Arm Label: Stratum 2/Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Stratum 1/ASA, Stratum 2/ASA | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Stratum 1/Rivaroxaban, Stratum 2/Rivaroxaban | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Stratum 1/ASA, Stratum 1/Rivaroxaban | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Stratum 2/ASA, Stratum 2/Rivaroxaban
B: Arm Label: Aspirin + clopidogrel + oral anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Arm Label: Oral anticoagulants + clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Intervention Type: DEVICE; Name: PCI (percutaneous coronary intervention); Assigned to Arm(s): Aspirin + clopidogrel + oral anticoagulation, Oral anticoagulants + clopidogrel
C: Arm Label: Rivaroxaban 2.5mg + Aspirin 100mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban 5mg + Aspirin Placebo; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban Placebo + Aspirin 100mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: Rivaroxaban placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Aspirin placebo; Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole placebo; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg
D: Arm Label: OAC alone; Type: EXPERIMENTAL; Interventions: Drug: OAC alone | Arm Label: OAC plus single APT; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: OAC alone; Assigned to Arm(s): OAC alone

Answer: D